Recorded Presentation from the NCCN 2016 Congress Webinar Series: Immunotherapies in Cancer - Melanoma
Immunotherapy is emerging as a novel modality for controlling cancer and has been proposed as becoming the fourth cornerstone of cancer treatment along with surgery, radiotherapy, and chemotherapy. Compared to other systemic therapies, immunotherapy relies on the immune system and has the potential to overcome cancer evasion mechanisms and provide long-term cancer control or even cure.
Immunotherapy is distinct from other treatment modalities; instead of directly targeting the tumor, it aims at strengthening or triggering the immune system to respond to the malignancy. The potential for long-term immune memory contributes to the prevention of relapse and even a life-long cure. Harnessing the inherent immune system in the patient body can potentially lower acute toxicity to normal tissue compared to cytotoxic chemotherapy. Intense research has led to increased understanding of the mechanisms of immunosurveillance and helped with the development of novel therapies that augment the immune response in innovative ways.
This series is designed to educate healthcare professionals on current and emerging scientific data and to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting when managing patients with kidney cancer, non-small cell lung cancer, or melanoma who are being treated with immunotherapies.
This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer who are being treated with immunotherapies.
Following this activity, participants should be able to:
- Evaluate key considerations when choosing among the recommended immunotherapy options for adjuvant treatment of resected stage III disease or metastatic or unresectable melanoma.
- Assess patient and disease characteristics that determine whether intralesional injection is an appropriate treatment option for a patient with in-transit disease.
- Of the immunotherapy regimens recommended for melanoma, identify those that are associated with the highest risk of immune-related toxicities.
Anthony J. Olszanski, MD
Fox Chase Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below have disclosed the following relevant financial relationships:
Anthony J. Olszanski, MD
Bristol-Myers Squibb Company: Scientific Advisor
Churchill Consulting, a Division of CruxQS: Scientific Advisor
Merck & Co., Inc.: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor
The activity planning staff listed below has no relevant financial relationships to disclose:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Anita Engh, PhD; Rashmi Kumar, PhD; Nicole McMillian, MS
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.98 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-111-H01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 0.98 ANCC contact hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing